Libido has a genetic architecture — DRD2 receptor density, OXTR bonding sensitivity, MTNR1B circadian timing, and MC4R central arousal signaling all shape sexual desire at the neurochemical level. The Precision Peptide Genetic Test maps these variables as part of 14 pathways, 49 peptides, and 150+ genetic insights, explaining the biology of desire that testosterone panels miss.

Sexual wellness has a genetic architecture — six biological variables that determine how your body produces arousal, routes blood flow, generates desire, and responds to intimacy. The Precision Peptide Genetic Test maps all six as part of 14 pathways, 49 peptides, and 150+ genetic insights, answering the question that hormone panels and bloodwork alone cannot.

Central sexual arousal — the brain-driven signal that initiates the entire sexual response cascade — runs through the melanocortin pathway and its primary receptor, MC4R. The Precision Peptide Genetic Test analyzes melanocortin pathway variants as part of 14 pathways, 49 peptides, and 150+ genetic insights, mapping the CNS architecture of arousal that vascular testing cannot reach.

OXTR encodes the oxytocin receptor that governs bonding, arousal facilitation, and the neurochemistry of intimacy in both men and women. The Precision Peptide Genetic Test analyzes OXTR variants as part of 14 pathways, 49 peptides, and 150+ genetic insights — mapping the social bonding dimension of sexual health that hormone panels cannot measure.

DRD2 encodes the D2 dopamine receptor that governs the motivation, anticipation, and reward dimensions of sexual desire. The Precision Peptide Genetic Test analyzes DRD2 variants as part of 14 pathways, 49 peptides, and 150+ genetic insights — mapping the neurochemical foundation of sexual drive that no testosterone panel captures.